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ABSTRACT
Endometrial cancer arises from the endometrium. It has a slow progression 
and a reported survival rate of 75%. The identification of soluble biomarkers in the 
uterine aspirate may be very useful for its early diagnosis. Uterine aspirates from 
10 patients with endometrial cancer and 6 non-endometrial cancer controls were 
analyzed by two-dimensional gel electrophoresis coupled with mass spectrometry 
and western blotting for data verification. A total of 25 proteins with fold change in 
%V ≥2 or ≤0.5 in intensity were observed to change significantly (P<0.05). From 
the discovery phase, four proteins (costars family protein ABRACL, phosphoglycerate 
mutase 2, fibrinogen beta chain, annexin A3) were found to be present in the uterine 
aspirate of endometrial cancers and not in healthy aspirates. Western blotting 
verification data demonstrated that costars family protein ABRACL, phosphoglycerate 
mutase 2 were present only in endometrial cancer uterine aspirate while fibrinogen 
beta chain, annexin A3 were also present in healthy aspirates. To our knowledge, 
phosphoglycerate mutase 2 has not been previously associated with endometrial 
cancer. In this study we demonstrate that uterine aspirates are a promising biological 
fluid in which to identify endometrial cancer biomarkers. In our opinion proteins like 
costars family protein ABRACL and phosphoglycerate mutase 2 have a great potential 
to reach the clinical phase after a validation phase.
INTRODUCTION
Endometrial cancer (EC) is the most common 
gynecological malignant neoplasm [1, 2].
In Italy it represents the fourth malignant tumor in 
women (5% of all tumors) after breast, colon and lung 
cancers, and the third if we consider women between 50 
and 69 years of age (7%). Its incidence shows a slight 
upward time trend (+ 0.7% / year), while mortality has 
decreased in the last 10 years with the 5-year survival rate 
rised from 73% in 1990 to 77.5% in 2007 [3]. Nowadays, 
the majority of cases are diagnosed at early stages, while 
only 30% of EC patients are diagnosed at an advanced 
stage of the disease [4].
Abnormal uterine bleeding (AUB) is generally 
the first sign of the disease but AUB occurs in almost 
all women over the age of 45. Other symptoms include 
pain, bleeding, infection, and uterine perforation. 
Diagnosis relies on the results of the endometrial 
biopsy.
Early detection improves the chances that the 
endometrial cancer will be treated successfully.
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Several risk factors are already known and include: 
diabetes mellitus, breast cancer, dietary, obesity, high 
levels of estrogen, and increasing age [5, 6].
Studies have established the involvement of defects 
in DNA mismatch repair genes, microsatellite instability, 
and mutations in the PTEN and K-ras and/or B-catenin 
genes and p53 suppressor gene with mutation of Her-2/neu 
in endometrial cancer physiopathology [7].
Proteins play a key role in several cellular processes 
and are often associated with diseases, including cancer. 
The search for EC biomarkers has been mostly based 
on tissue analyses. Li and colleagues identified CypA, 
E-FABP, CAPS as potential EC-associated proteins by 
using 2-DE coupled with mass spectrometry [8]. Multiple 
members of peroxiredoxin [9], members of the annexin 
family [9], prohibitin 2 and bone marrow stromal antigen 
2 [10] were identified by proteomics technique as potential 
biomarkers or potential therapeutic targets in endometrial 
cancer. However, the detection of these proteins has not 
led to their use as biomarkers in clinical practice.
Biological fluids are rich with proteins and the 
different abundance of these proteins can indicate the 
presence of tumors and are thus valuable markers for the 
development of noninvasive diagnostic tests [11]. A little 
number of proteomic studies have been performed on 
uterine aspirates without a focus on EC biomarkers [12, 
13].
Martinez-Garcia et al. conducted the first study 
focused on EC uterine aspirate using LC-PRM for 
biomarker identification [14].
An ideal biomarker research should be based 
on three sequential steps: discovery, verification and 
validation [15]. Obviously, the discovery phase produces a 
long list of biomarkers using a limited number of samples, 
that will need to be verified before entering the validation 
phase.
Two-dimensional gel electrophoresis (2-DE) is a 
powerful method for quantitative comparative proteomic 
studies, able for simultaneous resolution of thousands of 
proteins including isoform or protein PTM. 2-DE was used 
for the identification of biomarkers for several types of 
cancers [16, 17] but also to give more detailed information 
about these proteins as the presence of alternative splicing 
and/or isoforms.
The aim of the present study is the identification and 
verification of soluble biomarkers in the uterine aspirates 
of ECs, which could be then verified in a further validation 
phase.
RESULTS
2-DE and MS
In the present study, the uterine aspirate of six 
non-EC controls and ten women suffering from EC were 
resolved using 2-DE. More than a thousand protein spots 
were detected in each gel. For 2-DE analysis, 40 gels were 
used and the effectiveness of average-matching between 
each gel and the corresponding “Master gel” was 80% of 
the total number of spots. The analysis revealed 28 protein 
spots with different abundance in the uterine aspirate of 
the ECs, which corresponded to 25 proteins. Only protein 
spots significantly different between EC and control 
(P<0.05) and with a fold change in %V ≥2 or ≤0.5 were 
considered (Figure 1).
These proteins were identified by MALDI-TOF/
TOF and LTQ-Orbitrap XL, and database searched 
against the human section of the UniProt database (version 
20150401; 90,411 sequences) (Table 1).
We performed a ROC analysis to determine the 
sensitivity and specificity of each biomarker. The best-
performing individual protein controls (sensitivity 100%, 
specificity 100%) (Supplementary Table 2) were: PDIA3, 
isoform 2 of CAPS, isoform CRA_a PRDX2, ABRACL, 
NME2, Isoform 2 ASRGL1, GAPDH, isoform 2 ANXA7, 
ENO1, CORO1A, C11orf54, PGAM2, FGB, ANXA3, 
PGK1. Of these, ABRACL, PGAM2, FGB, ANXA3 
were present only in EC. Based on this data we decided 
to validate ABRACL, PGAM2, FGB, ANXA3 by western 
blotting.
Functional analysis of the EC aspirate proteome
The 25 identified proteins were divided into groups, 
based on the PANTHER classification system, according 
to their biological processes and molecular functions. In 
terms of biological processes, proteins were grouped into 
four main categories: metabolic process, cellular process, 
response to stimulus and biological regulation (Figure 2). 
For molecular function the proteins were grouped into 
three categories: catalytic activity, binding, antioxidant 
activity (Figure 3). Fifteen of these proteins (PGAM2, 
IDH1, C11orf54, GSS, NME2, GAPDH, PSME1, PDIA3, 
FAH, PGK1, LDHB, ASRGL1, SOD2, ENO1, CNDP2) 
were found to be associated with the catalytic activity, 
according to the PANTHER prediction (Table 1). These 
data show the involvement of different types of enzymes 
in endometrial cancer disease.
Western blotting analysis
In this study, western blot (WB) analysis from 
ten endometrial cancer vs six normal endometrium was 
used to validate the abundance of the four proteins which 
discriminate unambiguously between cases and controls 
(ABRACL, PGAM2, FGB, ANXA3). As seen from Figure 
4, only ABRACL and PGAM2 are able to unambiguously 
discriminate the controls, from the EC patients.
The western blot data verified the presence of 
PGAM2 in all EC patients, behaving as a marker for G1, 
G2, G3, G2-G3 and serous papillary adenocarcinoma EC 
phase.
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For ABRACL, western blotting verified its presence 
in eight EC patients G1, G2, G3, serous papillary 
adenocarcinoma phase, while we did not observe the 
presence of ABRACL in one G2 and one G2-G3 phase.
In case of FGB, we found the protein in all the EC 
samples but this protein was also present in the samples 
of two healthy subjects (hyperplastic endometrium 
and normal endometrium). For ANXA3 we found this 
protein in nine EC samples. This protein was absent in 
G3 samples and was found in three healthy patients 
(hyperplastic endometrium and two normal endometrium). 
FGB and ANXA3 were not able to discriminate the normal 
endometrium from the EC, although their expression level 
is significantly increased in EC.
DISCUSSION
To date, several studies have been carried out for 
the identification of EC biomarkers, but no protein has 
yet reached the stage of clinical application. This may 
be related to the lack of studies on biofluids for the 
identification of soluble biomarkers and overall to the 
difficulty in performing such kind of studies on large 
cohorts of samples for the validation phase. The studies 
conducted until now focused on tissues and on plasma/
serum [18, 19]. However, the research for biomarkers in 
serum/plasma is very difficult due to the large dynamic 
range of protein concentration and the low concentration 
of the potential biomarkers [20, 21].
To our knowledge, our study is the first using 2-DE 
with SYPRO Ruby and data verification by western 
blotting in the EC uterine aspirate. We identified 25 
potential biomarkers, but only four of them were present 
only in ECs. Further data validation by western blotting 
showed that ABRACL and PGAM2 fully discriminate the 
healthy from EC samples. Our verification data showed 
the presence of PGMA2 in all EC patients. This protein 
has the potential to be identified as a biomarker for all 
EC phases and in serous papillary adenocarcinoma. While 
ABRACL verification data showed the presence of this 
protein in eight EC patients, only two samples (G2 and 
G2-G3 phase) did not show the presence of this protein, 
and this may be associated with the low abundance of 
these protein in the samples. However, the protein may 
be a potential biomarker for EC in G1, G2, G3 and serous 
papillary adenocarcinoma.
Maxwell GL at colleagues conducted a detailed 
study on the proteomic profile of EC and endometrium 
samples using label-free GeLC-MS/MS [9]. We compared 
our data with their data. The comparison confirmed 
Figure 1: Two-dimensional electrophoresis map of the normal endometrium uterine aspirate and endometrial 
cancer uterine aspirate proteome. Immobilized pH gradient pH 3-10 non-linear strips were used for the first dimension and 12% 
polyacrylamide gels were used for the second dimension.
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Table 1: List of proteins with significantly different abundance in the uterine aspirate of the endometrial cancer 
compared to the aspirate of healthy controls, as identified by MALDI-TOF/TOF or LTQ-Orbitrap XL mass 
spectrometry, and classified by their corresponding molecular function. Only the most relevant molecular and 
cellular functions are reported
Accession no Spot 
no
Protein description Gene 
symbol
Protein score Molecular 
function
Fold 
changea
P-value
Q9P1F3 8 Costars family protein ABRACL ABRACL 52.25 Not known 490 0.0273
P02675 21 Fibrinogen beta chain FGB 246.69 Binding 400 0.0050
P15259 20 Phosphoglycerate mutase 2 PGAM2 130.55 Catalytic activity 230 0.0431
P06733 15 Alpha-enolase ENO1 339.27 Catalytic activity 220 0.0431
P12429 23 Annexin A3 ANXA3 480.59 Binding 180 0.0273
P20073-2 13 isoform 2 of Annexin A7 ANXA7 366.98 Binding 150 0.0412
P06733 14 Alpha-enolase ENO1 50.65 Catalytic activity 120 0.0431
A6NIW5 7 Peroxiredoxin 2, isoform CRA_a PRDX2 138.93
Antioxidant 
activity 60 0.0431
A0A087WT99 19 Ester hydrolase C11orf54 C11orf54 76.43 Catalytic activity 60 0.0431
P04406 12
Glyceraldehyde-
3-phosphate 
dehydrogenase
GAPDH 291.10 Catalytic activity 50 0.0422
P28072 5 Proteasome subunit beta type-6 PSMB6 82.33
Catalytic activity/
binding 20 0.0251
P48637 4 Glutathione synthetase GSS 506.38 Catalytic activity 15 0.0277
J3KPD9 10
Nucleoside 
diphosphate kinase 
B
NME2 330.20 Catalytic activity 15 0.0277
Q7L266-2 9
Isoform 2 
Isoaspartyl 
peptidase/L-
asparaginase
ASRGL1 126.66 Catalytic activity 11.5 0.0431
P00558-2 25
Isoform 2 of 
Phosphoglycerate 
kinase 1
PGK1 132.98 Catalytic activity 10 0.0180
P31146 18 Coronin-1A CORO1A 70.29 Binding 8.5 0.0431
P16930-2 17 isoform 2 of Fumarylacetoacetase FAH 50.32 Catalytic activity 7 0.0277
F5H3C5 11 Superoxide dismutase SOD2 108.73 Catalytic activity 5 0.0218
(Continued)
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Accession no Spot 
no
Protein description Gene 
symbol
Protein score Molecular 
function
Fold 
changea
P-value
Q13938-3 6 isoform 2 of Calcyphosin CAPS 235.58 Binding 5 0.0431
Q06323-3 24
isoform-3 
Proteasome 
activator complex 
subunit 1
PSME1 73.07 Catalytic activity 3.3 0.0180
P30101 3 Protein disulfide-isomerase A3 PDIA3 253.77 Catalytic activity 3.3 0.0277
O75874 16
Isocitrate 
dehydrogenase 
[NADP] 
cytoplasmic
IDH1 698.72 Catalytic activity 3.2 0.0180
P06733 26 Alpha-enolase ENO1 373.86 Catalytic activity 2.9 0.0284
P07195 22
L-lactate 
dehydrogenase B 
chain
LDHB 239.73 Catalytic activity 2 0.0241
Q96KP4 2 Cytosolic non-specific dipeptidase CNDP2 186.34 Catalytic activity 0.3 0.0116
A0A0C4DGB6 1 Serum albumin ALB 183.91 Binding 0.1 0.0249
aFold change was defined as the ratio of the mean %V according to the formula %V=Vsingle spot/Vtotal spot of cases vs. 
controls.
Figure 2: PANTHER classification of proteins upregulated in leiomyoma according to their biological process and 
molecular function. 
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Figure 3: PANTHER classification of proteins upregulated in leiomyoma according to their molecular function. 
Figure 4: Western blot analysis of PGAM2, ABRACL, ANXA3, FBG normal endometrium uterine aspirate and 
endometrial cancer uterine aspirate.  The intensities of the immunostained bands were normalized with the protein intensities 
measured by Coomassie blue from the same blot. The bar graph shows the relative expression (band density) of proteins in the normal 
endometrium uterine aspirate and endometrial cancer uterine aspirate. The results are shown as a histogram (mean) with error bars 
representing the standard deviation. All differences were observed to be significant (Wilcoxon signed-rank test for matched samples, 
P<0.05).
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that the expression of FGB, ENO1, ANXA3, PRDX2, 
GAPDH, PSMB6, GSS, ASRGL1, PGK1, CORO1A, 
PSME1, PDIA3, IDH1, LDHB was upregulated. In 
Martinez-Garcia et al., ENO1 was confirmed as an up-
regulated protein in endometrial cancer [14].
DeSouza L et al. studied the proteomic profile of 
EC and endometrium samples using labeled tags iTRAQ 
and cICAT: NME2, SOD2, CAPS were upregulated while 
ALB was down-regulated [22].
Our proteomic study revealed the dysregulation of 
fifteen metabolic enzymes showing a clear disruption of 
cancer metabolism.
ABRACL is a 82 amino acid protein that increase 
actin dynamics and cell motility [23].
PGAM2 is a glycolytic enzyme that catalyzes the 
reversible conversion of 3-phosphoglycerate (3-PG) to 
2-phosphoglycerate, which is highly expressed in muscle 
tissues [24]. This enzyme increase NADPH homeostasis 
in response to the oxidative stress that impacts cell 
proliferation and tumor growth [25]. Further studies with 
larger groups of patients and controls are needed for the 
validation of ABRACL and PGAM2 as biomarkers.
Both proteins are involved in cell motility and 
proliferation, and in our opinion further studies are 
needed to verify the association between the expression 
of these proteins and tumor metastatization. In addition, 
PGAM2 being a glycolytic enzyme can be very useful in 
monitoring glycolysis as a fundamental metabolic pathway 
in cancer development.
In this study we demonstrate that uterine aspirates 
are a valuable biological fluid for the identification of 
cancer biomarkers.
The use of diagnostic biomarkers for EC can fasten 
the diagnostic process and reduce the sanitary costs.
Uterine aspirate may be an alternative to serum/
plasma due to its high specificity [14].
In conclusion, our study expands the knowledge 
on the search for biomarkers in EC uterine aspirates. 
This study confirms the potential of 2-DE for biomarker 
discovery and western blotting for data verification. 
Proteins like ABRACL and PGAM2 have a great potential 
to reach the clinical phase after a validation phase.
MATERIALS AND METHODS
Patients, sample collection and treatment
A total of 16 patients (10 women suffering 
from EC and 6 non-EC controls) were recruited at the 
Institute for Maternal and Child Health – IRCCS “Burlo 
Garofolo” (Trieste, Italy) during 2014 and 2015. All 
procedures complied with the Declaration of Helsinki 
and were approved by the Technical and Scientific 
Committee of the Institute for Maternal and Child 
Health – IRCCS “Burlo Garofolo” (approval no. RC 
19/08). All patients signed an informed consent. The 
clinical and pathological characteristics of the patients 
are described in Supplementary Table 1. Samples from 
control patients were obtained during the proliferative 
phase endometrium and the median age was 43 years. 
Samples from patients with endometrial cancer were 
obtained during postmenopause and the median age was 
72.5 years.
Uterine aspirates were collected by aspiration with 
a Cornier Pipelle in the office of the clinician or in the 
operating room prior to surgery, and transferred to 10 
ml microtubes and 3 ml of NaCl 0.9% was added with a 
protease inhibitor mixture (2 mM phenylmethylsulfonyl 
fluoride, 1 mM benzamidine, 1 mM EDTA and 10 mM 
NaF). The supernatant was centrifuged at 5,000 x g for 
30min at 4˚C followed by centrifugation at 15,000 x g 
for 30min at 4˚C to remove cell debris. Approximately 
3 ml of supernatant was desalted and concentrated using 
an Ultrafree-4 Centrifugal Filter Unit (EMD Millipore, 
Billerica, MA, USA) with a molecular weight cut-off of 
3 kDa at 4,000 x g at 25˚C until the remaining volume 
reached 50 μl. The protein content of the supernatant was 
determined by Bradford assay.
2-DE and image analysis
2-DE was performed like previously described [26]. 
For 2-DE analysis, 400 μg of proteins from each uterine 
aspirate sample was denatured in 300 μl of dissolution 
buffer [7 M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate, 40 mM Tris, 65 
mM dithiothreitol (DTT) and 0.24% Bio-Lyte 3/10 (Bio-
Rad Laboratories, Inc., Hercules, CA, USA)] and a trace 
of bromophenol blue. ReadyStrip™ pH 3-10 Non-linear 
(NL) 18-cm immobilized pH gradient (IPG) strips (Bio-
Rad Laboratories, Inc.) were rehydrated in a dissolution 
buffer at 50 V for 12h at 20˚C, and isoelectric focusing 
(IEF) was performed in a PROTEAN IEF Cell (Bio-
Rad Laboratories, Inc.). After the IEF, serial incubations 
were performed: first, the IPG strips were equilibrated 
for 20min in an equilibration buffer [6 M urea, 2% SDS, 
50 mM Tris-HCl (pH 8.8), 30% glycerol and 1% DTT] 
and then in another equilibration buffer containing 4% 
iodoacetamide instead of DTT. For the second dimension, 
the equilibrated IPG strips were transferred to a 12% 
polyacrylamide gel. After electrophoresis, gels were 
fixed in 40% methanol and 10% acetic acid for 1h, and 
then stained for 16h with SYPRO Ruby. These gels, 
after SYPRO Ruby destaining, were stained for 48h with 
colloidal Coomassie Brilliant Blue. Double experimental 
replicates were performed per sample. Molecular weights 
were determined by comparison with Precision Plus 
Protein™ Prestained Standards (Bio-Rad Laboratories, 
Inc.), covering a range from 10 to 250 kDa. 2-DE gels 
were scanned with a Molecular Imager PharosFX System 
and analyzed using the Proteomweaver 4.0 software (both 
from Bio-Rad Laboratories, Inc.).
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Quantification of spot levels
2-DE image analysis was performed using the 
Proteomweaver 4.0 software. The analysis was performed 
by matching all gels from each uterine aspirate sample 
with a reference gel for the same condition, having the 
best resolution and the greatest number of spots, named 
“Master gel”.
Differences were considered to be significant when 
the ratio of the mean percentage of relative volume (%V), 
determined as %V = Vsingle spot/Vtotal spot, was ≥2.0 
for up-regulated or ≤ 0.5 for down-regulated proteins, and 
the non-parametric Wilcoxon signed-rank test for matched 
samples resulted as being significant (P<0.05). Fold 
change was calculated as the ratio between the mean %V 
of the EC uterine aspirate and that of the normal uterine 
aspirate.
Western blotting
Protein extracts (30 μg) used for 2-DE were 
separated by 12% or 15% SDS-PAGE and then transferred 
to a nitrocellulose membrane. The residual binding sites 
on the membrane were blocked by treatment with 5% dry 
milk in TBS-tween 20. After milk saturation the membrane 
was incubated overnight at 4˚C with 1:200 diluted 
primary rabbit polyclonal antibody against ABRACL, 
1:200 diluted primary rabbit polyclonal antibody against 
FGB, 1:1000 diluted primary rabbit polyclonal antibody 
against ANXA3, 1:300 diluted primary rabbit polyclonal 
antibody against PGAM2. The membrane was washed 
three times in TBST for 10min, and then incubated for 
90min at 4˚C with a horseradish peroxidase-conjugated 
anti-rabbit immunoglobulin G antibody (Sigma-Aldrich; 
Merck KGaA) at 1:3.000 dilution. Protein expression was 
visualized by chemiluminescence (SuperSignal West Pico 
Chemiluminescent Substrate; Thermo Fisher Scientific, 
Inc.), and the intensity of the signals was quantified 
by VersaDoc Imaging System (Bio-Rad Laboratories, 
Inc.). The intensities of the immunostained bands were 
normalized with the protein intensities measured by 
Coomassie blue (Sigma-Aldrich; Merck KGaA) from the 
same blot.
Trypsin digestion and MS analysis
Spots from 2-DE were digested with sequencing 
grade-modified trypsin (Promega, Madison, WI, USA) 
and analyzed by mass spectrometry, as described by Ura 
et al. [27].
Spots extracted from 2-DE gels were washed with 
50 mM NH4HCO3 and acetonitrile (ACN; Sigma-Aldrich) 
and dried under vacuum in a SpeedVac system. To each 
spot, three microliters of 12.5 ng/μl sequencing grade 
modified trypsin (Promega, Madison, WI, USA) in 50 
mM NH4HCO3 were added, samples were allowed the 
rehydrate at 4°C and then covered with 50 mM NH4HCO3 
and digested overnight at 37˚C. Peptides were extracted 
with three changes of 50% ACN/0.1% formic acid (FA; 
Fluka), dried under vacuum and dissolved in 10 μl of 0.1% 
trifluoroacetic acid (TFA; Riedel-de Haën).
One microliter of matrix solution (α-cyano-
4hydroxycinnamic acid 5 mg/ml in 70% acetonitrile/0.1% 
TFA) was mixed with 1 μl of each sample, and 0.8 μl 
of the final sample/matrix mixture was spotted onto 
a stainless steel MALDI target plate. Tandem mass 
spectrometry (MS/MS) analysis was performed on a 
MALDI-TOF/TOF 4800 mass spectrometer (AB Sciex, 
Framingham, MA, USA) in a data dependent mode: a full 
MS scan was acquired, followed by MS/MS spectra of the 
10 most intense signals.
Samples that could not be identified by MALDI-
TOF/TOF analysis were further analyzed by LC-MS/
MS on an LTQ-Orbitrap XL mass spectrometer (Thermo 
Fisher Scientific, Rockford, IL, USA), coupled with a 
nano-HPLC Ultimate 3000 (Dionex – Thermo Fisher 
Scientific). The analysis was performed in a data 
dependent mode, and a full scan at 60,000 resolution 
on the Orbitrap was followed by MS/MS fragmentation 
scans on the 10 most intense ions acquired with CID 
fragmentation in the linear trap.
Data were converted into MGF (Mascot generic 
format) files to be elaborated with Proteome Discoverer 
1.4 (Thermo Fisher Scientific), while raw data files from 
the LTQ-Orbitrap XL mass spectrometer were directly 
analyzed with the software. Proteome Discoverer was 
interfaced to a Mascot search engine, version 2.2.4 (Matrix 
Science, London, UK).
Enzyme specificity was set to trypsin with 1 missed 
cleavage. The database used for protein identification was 
UniProt Human (version 20150401; 90,411 sequences).
The tolerances were 50 ppm (parent) and 0.3 
Da (fragment ions) for the MALDI-TOF/TOF data, 
and were set to 10 ppm for parent mass and to 0.6 Da 
for fragment ions for the files from LTQ-Orbitrap XL. 
Carbamidomethylation of cysteine residues was set to 
‘fixed modification’ and methionine oxidation to ‘variable 
modification’.
A false discovery rate (FDR) was calculated by 
Proteome Discoverer based on the parallel search against a 
randomized database. Proteins were considered as positive 
hits if at least two independent peptides were identified 
with medium (95%) or high (99%) confidence.
Functional analysis
The different abundant proteins identified were 
analyzed by PANTHER 11.0 (Protein Analysis through 
Evolutionary Relationships; http://www.pantherdb.
org). Proteins were then classified according to their 
involvement in biological processes and molecular 
function. As most of the proteins take part in multiple 
processes, only the most relevant were reported.
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Statistical analysis
Statistical analyses were carried out with the 
non-parametric Wilcoxon signed-rank test for matched 
samples for both 2-DE and western blot data. P<0.05 was 
considered to indicate a statistically significant difference. 
All analyses were conducted with Stata/IC 14.1 for 
Windows (StataCorp LP, College Station, TX, USA).
Abbreviations
 MALDI-TOF/TOF- Matrix-assisted laser desorption/ 
ionization
 LC-PRM- Targeted Proteomics by Parallel-Reaction 
Monitoring
 LTQ Orbitrap XL- Hybrid Ion Trap-Orbitrap Mass 
Spectrometer
NaCl- Sodium chloride
EDTA- Ethylenediaminetetraacetic acid
NaF- Sodium fluoride
SDS- Sodium Dodecyl Sulphate
 Tris-HCL- 2-Amino-2-(hydroxymethyl)-1,3-
propanediol hydrochloride
IPG- Immobilized pH gradient
 SDS-PAGE- Sodium Dodecyl Sulphate - Poly-
Acrylamide Gel Electrophoresis
NH4HCO3- Ammonium bicarbonate
 LC-MS/MS- Liquid chromatography–mass 
spectrometry.
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